You are here

  • Home
  • Archive
  • Volume 16, Issue 1
  • Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation

Article info

Article menu
Download PDFPDF
Case Reports: Novel treatment (new drug/interventions; established drug/procedure in new situation)
Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation

Authors

  • Benjamin T Berger Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA PubMed articlesGoogle scholar articles
  • Matthew K Labriola Department of Medicine, Duke University Medical Center, Durham, North Carolina, USADuke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina, USA PubMed articlesGoogle scholar articles
  • Emmanuel S Antonarakis Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Academic Health Center, Minneapolis, Minnesota, USA PubMed articlesGoogle scholar articles
  • Andrew J Armstrong Department of Medicine, Duke University Medical Center, Durham, North Carolina, USADuke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Benjamin T Berger; benjamin.t.berger{at}duke.edu; Dr Andrew J Armstrong; andrew.armstrong{at}duke.edu
View Full Text

Citation

Berger BT, Labriola MK, Antonarakis ES, et al
Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation
BMJ Case Reports CP 2023;16:e251320.

Publication history

  • Accepted December 13, 2022
  • First published January 18, 2023.
Online issue publication 
January 31, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.